

FiercePharma

< Select another site | Advertise | Contact

SEARCH



Free Daily Pharma Industry Newsletter Every business day, *FiercePharma* updates pharmaceutical executives on the latest Pharma industry news and deals. Stay up to date on:

Pharma Company News | Generic Drug Companies | Pharmaceutical Marketing & Sales | FDA Regulations & Warnings | Phase IV Clinical Trials

[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers' trust comes first.



EMAIL ADDRESS

SIGN ME UP

FiercePharma

NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE

FOLLOW US



Topics: Financials

EP Vantage: Eliquis projected sales off 60% for 2014

Evaluation shows analysts' hopes for anticoagulant fall as sales remain weak

October 18, 2013 | By Eric Palmer

SHARE



TOOLS



Comment



Print



Contact Author



Reprint

When Eliquis was first released to the market, execs with partners Bristol-Myers Squibb (\$BMY) and Pfizer (\$PFE) cautioned that it would have a

slow release. It was the third entrant in the [warfarin](#) alternative market behind Boehringer Ingelheim's [Pradaxa](#) and Johnson & Johnson (\$JNJ) and Bayer's [Xarelto](#). But data were on their side and they, and analysts, predicted big things for the new drug. However, an evaluation of data from drug information specialist EvaluatePharma finds that optimism is quickly waning as sales for Eliquis remain weak.



According to an EP Vantage report provided in abbreviated form to *FiercePharma*, analysts' predictions for 2014 sales of the anticoagulant have fallen 60% in the last 12 months. They now stand at \$491 million. That is as projections for 2014 sales of Xarelto have surged by 81% and 60% in the respective territories for J&J and Bayer, to \$1 billion and \$1.4 billion. EP Vantage believes the dosing advantage and broader label for that drug "might have been underestimated."



[Webinar] Drug Manufacturing Solutions in a Complex Industry

DATE: WEDNESDAY, FEBRUARY 24, 2016 | 10AM ET / 7AM PT

The clinical and commercial success of a new chemical entity (NCE) requires pre-formulation studies of drug candidates and development of suitable formulations based on the physicochemical and biopharmaceutical properties. Through expert content and case study examples, this webinar will highlight the strategies and state-of-art screening, particle size reduction and formulation technologies to optimize the properties and formulation of your drug candidates. [Reserve Your Spot Today!](#)

Sign up for our **FREE** newsletter for more news like this sent to your inbox!

While it was late to the market, the advantages of Eliquis had led analysts to believe it would take the market by storm. Eliquis and Pradaxa are both better than warfarin in preventing stroke. Only Eliquis, however, reduced major bleeding over warfarin and improved mortality. In fact, the Institute for Safe Medication Practices (ISMP) this week [flagged its latest set of side-effect reports](#) to the FDA, putting anticoagulant drugs at the top with Pradaxa leading the pack.

JOIN 150,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get *FiercePharma* via daily email. Sign up today!

EMAIL ADDRESS

SIGN ME UP

POPULAR STORIES

MOST READ MOST SHARED

Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad

Top exec exits as Pfizer redraws org chart for post-megamerger future

UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent

Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too

PhRMA kicks off new ad campaign to doctor pharma's tarred image

THE LIBRARY: MULTIMEDIA

FierceBiotech Radio on the burning hole in Gilead's \$25B pocket and AbbVie's future in hematology



| DECEMBER 10, 2015

FiercePharma's Carly Helfand and *FierceBiotech's* Damian Garde discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back at AbbVie's blockbuster buyout of Pharmacyclics and a consideration of how a certain biotech entrepreneur is bringing attention to an FDA loophole.

[MORE ITEMS](#)

The EP Vantage evaluation points out that Goldman Sachs analysts were so excited by the superiority of Eliquis that when the FDA approved the drug, they predicted first-year sales of \$350 million would be a "low hurdle." That looks to be way off now. Consensus for 2013 currently stands at \$129 million, and that may not be reachable, given that it sold only \$12 million in the second quarter. That was even worse than the disappointing \$17 million posted for the first quarter. The report points out that in their first full year on the market after being approved for stroke prevention, global sales of Pradaxa were \$875 million and \$582 million for Xarelto.

The lousy sales in the second quarter are well known to BMS investors, who had to endure the company cutting full-year revenue and earnings forecasts at the same time it announced the remarkably weak sales for Eliquis.

Supporters point out that it takes time for the benefits of the drug to be fully understood and that it can be really difficult to get doctors and patients to change from a protocol they are accustomed to. But EP Vantage says it now appears that is going to take a whole lot longer than analysts first expected.

- read the EvaluatePharma Vantage Point article

Special Report: Top 15 Drug Launch Superstars - Xarelto

Related Articles:

BMS, Pfizer say FDA to review Eliquis for new use

Faltering Eliquis leaves Bristol-Myers' Q2 sales in the lurch

Which new drugs promise to shake up markets the most?

Armed with EU stroke approval, Pfizer, BMS talk up Eliquis' edge over rivals

Safety group flags bleeding reports on Pradaxa, Xarelto and old standby warfarin

Filed Under Bristol-Myers Squibb, Eliquis, Pfizer

COMMENTS

Sponsored

FISHER INVESTMENTS

10 Ways to Generate Income in Retirement

If you have a \$500,000 portfolio, download the guide by Forbes columnist Ken Fisher's firm. It's called, "The Definitive Guide to Retirement Income."

[Learn More](#)



0 Comments

FiercePharma

[Login](#)

[Recommend](#)

[Share](#)

[Sort by Best](#)



Start the discussion...

Be the first to comment.

[Subscribe](#)

[Add Disqus to your site](#) [Add Disqus](#) [Add](#)

[Privacy](#)

DISQUS

LATEST COMMENTARY

[AstraZeneca chief chalks up milestones on his map to \\$45B](#)

[What's the calendar bringing biopharma next year? Our top 5 ideas](#)

[The most popular FiercePharma stories of 2015](#)

[Does new scrutiny threaten pharma's specialty-pharmacy strategy?](#)

[Pfizer responds to FiercePharma](#)

EVENTS

BioBasics: Biotech for the Non-Scientist Course

Course | March 3-4, 2016 — Washington DC — Sponsored By: FierceBiotech & Venable

BioBasics: Biotech for the Non-Scientist Course

Course | March 17-18, 2016 — Durham (RTP), NC — Sponsored By: FierceBiotech

PEGS the essential protein engineering summit

April 25 – 29, 2016 — Boston, MA

[MORE EVENTS](#)



